(Press-News.org) HEIDELBERG, 21 June 2013 – Researchers in Berlin and Munich, Germany and Oxford, United Kingdom, have revealed that a protein well known for its role in Alzheimer's disease controls spindle development in muscle and leads to impaired movement in mice when the protein is absent or treated with inhibitors. The results, which are published in The EMBO Journal, suggest that drugs under development to target the beta-secretase-1 protein, which may be potential treatments for Alzheimer's disease, might produce unwanted side effects related to defective movement.
Alzheimer's disease is the most common form of dementia found in older adults. The World Health Organization estimates that approximately 18 million people worldwide have Alzheimer's disease. The number of people affected by the disease may increase to 34 million by 2025. Scientists know that the protein beta-secretase-1 or Bace1, a protease enzyme that breaks down proteins into smaller molecules, is involved in Alzheimer's disease. Bace1 cleaves the amyloid precursor protein and generates the damaging Abeta peptides that accumulate as plaques in the brain leading to disease. Now scientists have revealed in more detail how Bace1 works.
"Our results show that mice that lack Bace1 proteins or are treated with inhibitors of the enzyme have difficulties in coordination and walking and also show reduced muscle strength," remarked Carmen Birchmeier, one of the authors of the paper, Professor at the Max-Delbrück-Center for Molecular Medicine in Berlin, Germany, and an EMBO Member. "In addition, we were able to show that the combined activities of Bace1 and another protein, neuregulin-1 or Nrg1, are needed to sustain the muscle spindles in mice and to maintain motor coordination."
Muscle spindles are sensory organs that are found throughout the muscles of vertebrates. They are able to detect how muscles stretch and convey the perception of body position to the brain. The researchers used genetic analyses, biochemical studies and interference with pharmacological inhibitors to investigate how Bace1 works in mice. "If the signal strength of a specific form of neuregulin-1 known as IgNrg1 is gradually reduced, increasingly severe defects in the formation and maturation of muscle spindles are observed in mice. Furthermore, it appears that Bace1 is required for full IgNrg1 activity. The graded loss of IgNrg1 activity results in the animals having increasing difficulties with movement and coordination," says Cyril Cheret, the first author of the work.
Drug developers are interested in stopping the Bace1 protein in its tracks because it represents a promising route to treat Alzheimer's disease. If the protein were inhibited, it would interfere with the generation of the smaller damaging proteins that accumulate in the brain as amyloid plaques and would therefore provide some level of protection from the effects of the disease. "Our data indicate that one unwanted side effect of the long-term inhibition of Bace1 might be the disruption of muscle spindle formation and impairment of movement. This finding is relevant to scientists looking for ways to develop drugs that target the Bace1 protein and should be considered," says Birchmeier. Several Bace1 inhibitors are currently being tested in phase II and phase III clinical trials for the treatment of Alzheimer's disease.
###
Bace1 and neuregulin-1 (Nrg1) cooperate to control formation and maintenance of muscle spindles
Cyril Cheret, Michael Willem, Florence R. Fricker, Hagen Wende, Annika Wulf- Goldenberg, Sabina Tahirovic, Klaus-Armin Nave, Paul Saftig, Christian Haass, Alistair N. Garratt, David L. Bennett and Carmen Birchmeier
Read the paper:
doi: 10.1038/emboj.2013.146
http://www.nature.com/emboj/journal/vaop/ncurrent/full/emboj2013146a.html
A Photo can be downloaded from the Internet at:
https://www.mdc-berlin.de/39833128/en/news/2013
Further information on The EMBO Journal is available at http://www.nature.com/embo
Media Contacts
Barry Whyte
Head | Public Relations and Communications
barry.whyte@embo.org
David del Alamo
Editor, The EMBO Journal
Tel: +49 6221 8891 309
david.delalamo@embo.org
About EMBO
EMBO is an organization of more than 1500 leading researchers that promotes excellence in the life sciences. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a European research environment where scientists can achieve their best work.
EMBO helps young scientists to advance their research, promote their international reputations and ensure their mobility. Courses, workshops, conferences and scientific journals disseminate the latest research and offer training in techniques to maintain high standards of excellence in research practice. EMBO helps to shape science and research policy by seeking input and feedback from our community and by following closely the trends in science in Europe.
For more information: http://www.embo.org
Alzheimer's disease protein controls movement in mice
2013-06-21
ELSE PRESS RELEASES FROM THIS DATE:
Iron dosing regimens affect dialysis patients' infection risk
2013-06-21
Washington, DC (June 20, 2013) — While intravenous iron is critical for maintaining the health of many dialysis patients, administering large doses over a short period of time increases patients' risk of developing serious infections, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Smaller doses given for a longer period of time appears to be much safer.
Dialysis patients often develop anemia, or low levels of red blood cells, and must receive intravenous treatments of iron to correct the condition. Unfortunately, ...
BigBrain: An ultra-high resolution 3-D roadmap of the human brain
2013-06-21
A landmark three-dimensional (3-D) digital reconstruction of a complete human brain, called the BigBrain, now for the first time shows the brain anatomy in microscopic detail—at a spatial resolution of 20 microns, smaller than the size of one fine strand of hair—exceeding that of existing reference brains presently in the public domain. The new tool is made freely available to the broader scientific community to advance the field of neuroscience.
Researchers from Germany and Canada, who collaborated on the ultra-high resolution brain model, present their work in the ...
Cities are a new kind of complex system: Part social reactor, part network
2013-06-21
Cities have long been likened to organisms, ant colonies, and river networks. But these and other analogies fail to capture the essence of how cities really function.
New research by Santa Fe Institute Professor Luis Bettencourt suggests a city is something new in nature – a sort of social reactor that is part star and part network, he says.
"It's an entirely new kind of complex system that we humans have created," he says. "We have intuitively invented the best way to create vast social networks embedded in space and time, and keep them growing and evolving without ...
Brain images of previously unattainable quality
2013-06-21
This news release is available in German. "BigBrain helps us to generate new knowledge on the healthy and also the diseased brain," says Katrin Amunts, director at the Institute of Neuroscience and Medicine (INM-1) and the C. and O. Vogt Institute of Brain Research at Heinrich Heine University Düsseldorf. For example: "As a consequence of its evolution, the human cerebral cortex is very heavily folded," says the neuroscientist. She explains that this is the reason why, in some areas, the thickness of the cerebral cortex can only be determined very imprecisely using ...
Men who can't produce sperm face increased cancer risk, Stanford-led study finds
2013-06-21
STANFORD, Calif. — Men who are diagnosed as azoospermic — infertile because of an absence of sperm in their ejaculate — are more prone to developing cancer than the general population, a study led by a Stanford University School of Medicine urologist has found. And a diagnosis of azoospermia before age 30 carries an eight-fold cancer risk, the study says.
"An azoospermic man's risk for developing cancer is similar to that for a typical man 10 years older," said Michael Eisenberg, MD, PhD, assistant professor of urology at the medical school and director of male reproductive ...
Daily iron during pregnancy linked to improved birth weight
2013-06-21
Taking iron daily during pregnancy is associated with a significant increase in birth weight and a reduction in risk of low birth weight, finds a study published on bmj.com today.
The effects were seen for iron doses up to 66 mg per day. The World Health Organization currently recommends a dose of 60 mg per day for pregnant women.
Iron deficiency is the most widespread nutritional deficiency in the world. It is the most common cause of anaemia during pregnancy, especially in low and middle income countries, affecting an estimated 32 million pregnant women globally in ...
Uncovering quantum secret in photosynthesis
2013-06-21
The efficient conversion of sunlight into useful energy is one of the challenges which stand in the way of meeting the world's increasing energy demand in a clean, sustainable way without relying on fossil fuels. Photosynthetic organisms, such as plants and some bacteria, have mastered this process: In less than a couple of trillionths of a second, 95 percent of the sunlight they absorb is whisked away to drive the metabolic reactions that provide them with energy. The efficiency of photovoltaic cells currently on the market is around 20 percent. What hidden mechanism does ...
Huge falls in diabetes mortality in UK and Canada since mid-1990s
2013-06-21
Both the UK and Canada have experienced huge falls in diabetes-related mortality since the mid-1990s, with the result that the gap in mortality risk between those with and without diabetes has narrowed substantially. The findings are in new research published in Diabetologia, the Journal of the European Association for the Study of Diabetes (EASD), and written by Dr Lorraine Lipscombe, Women's College Hospital, Women's College Research Institute, Toronto, ON, Canada, and Adjunct Scientist, Institute for Clinical Evaluative Sciences, Toronto, Canada; and Dr Marcus Lind, ...
Emergency helicopter airlifts help the seriously injured
2013-06-21
Patients transferred to hospital via helicopter ambulance tend to have a higher survival rate than those who take the more traditional road route, despite having more severe injuries. The research, published in BioMed Central's open access journal Critical Care suggests that air ambulances are both effective and worthy of investment.
Helicopters have been used as emergency ambulances for the past 40 years. For much of that time there has been ongoing debate about the cost of the service compared to the benefit in saving lives.
The TraumaRegister DGU® of the German ...
Frontiers news briefs: June 20
2013-06-21
Frontiers in Human Neuroscience
Agency matters! Social preferences in the three-person ultimatum game
The young field of "neureconomics" has shown that humans have a well-developed, innate sense of justice, presumably due to our evolutionary history as social animals. Johanna Alexopoulos and colleagues from the Medical University of Vienna, Austria, here show that two key variables determine whether we feel that a reward has been fairly distributed: how much we received compared to our peers, and how much influence we had over the distribution. Volunteers who were allowed ...